Wire
Virax Biolabs to Implement 1-for-25 Share Consolidation
Virax Biolabs (VRAX) said Wednesday its board approved a 1-for-25 share consolidation, effective June 26, following shareholder approval at an adjourned extraordinary general meeting held June 12.The biotechnology company said its ordinary shares will begin trading on a post-consolidation basis on the Nasdaq Capital Market at the opening of trading on June 26.Virax said the reverse stock split is intended to help the company regain compliance with the minimum bid price requirement of $1 per share and maintain its listing.Price: $0.12, Change: $-0.03, Percent Change: -19.95%
$VRAX
